Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: INF037
MIFTS: 56

Inflammatory Bowel Disease

Categories: Blood diseases, Bone diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Inflammatory Bowel Disease

About this section

MalaCards integrated aliases for Inflammatory Bowel Disease:

Name: Inflammatory Bowel Disease 12 36 29 6 3 15 17
Inflammatory Bowel Diseases 54 43 15 71
Bowel Disease, Inflammatory 39

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Gastrointestinal diseases Bone diseases Blood diseases Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050589
KEGG 36 H01227
MeSH 43 D015212
NCIt 49 C3138
SNOMED-CT 67 24526004
UMLS 71 C0021390
Sources

Summaries for Inflammatory Bowel Disease

About this section
KEGG : 36 Inflammatory bowel disease (IBD) is a heterogeneous group of chronic disorders, which includes Crohn's disease and ulcerative colitis. Patients suffer chronically from abdominal pain, diarrhea, bleeding, and malabsorption. In most patients, these disorders are manifested in adolescence or adulthood, however, they may present in infancy and may be inherited as an autosomal recessive trait. It has been reported that mutations in genes encoding the IL10R subunit proteins were found in patients with early-onset enterocolitis, involving hyperinflammatory immune responses in the intestine. Additional genes associated with the disease have been identified.

MalaCards based summary : Inflammatory Bowel Disease, also known as inflammatory bowel diseases, is related to inflammatory bowel disease 8 and inflammatory bowel disease 7. An important gene associated with Inflammatory Bowel Disease is NRON (Non-Coding Repressor Of NFAT), and among its related pathways/superpathways are Inflammatory bowel disease (IBD) and Antigen processing and presentation. The drugs Copper and Clofazimine have been mentioned in the context of this disorder. Affiliated tissues include all parts of digestive tract, colon and t cells.

Disease Ontology : 12 An intestinal disease characterized by inflammation located in all parts of digestive tract.

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn's disease. Inflammation affects the entire digestive tract in Crohn's disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body's immune system.

Wikipedia : 74 Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine.... more...

Sources

Related Diseases for Inflammatory Bowel Disease

About this section

Diseases in the Inflammatory Bowel Disease family:

Inflammatory Bowel Disease 11 Inflammatory Bowel Disease 1
Inflammatory Bowel Disease 2 Inflammatory Bowel Disease 3
Inflammatory Bowel Disease 7 Inflammatory Bowel Disease 5
Inflammatory Bowel Disease 8 Inflammatory Bowel Disease 6
Inflammatory Bowel Disease 4 Inflammatory Bowel Disease 9
Inflammatory Bowel Disease 10 Inflammatory Bowel Disease 12
Inflammatory Bowel Disease 13 Inflammatory Bowel Disease 14
Inflammatory Bowel Disease 15 Inflammatory Bowel Disease 16
Inflammatory Bowel Disease 17 Inflammatory Bowel Disease 18
Inflammatory Bowel Disease 19 Inflammatory Bowel Disease 20
Inflammatory Bowel Disease 21 Inflammatory Bowel Disease 22
Inflammatory Bowel Disease 23 Inflammatory Bowel Disease 24
Inflammatory Bowel Disease 25, Autosomal Recessive Inflammatory Bowel Disease 26
Inflammatory Bowel Disease 27 Inflammatory Bowel Disease 28, Autosomal Recessive
Inflammatory Bowel Disease 29 Inflammatory Bowel Disease 28
Inflammatory Bowel Disease 25 Rare Inflammatory Bowel Disease

Diseases related to Inflammatory Bowel Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1176)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 8 35.4 NOD2 IBD8
2 inflammatory bowel disease 7 35.3 NOD2 IBD7
3 inflammatory bowel disease 9 35.3 NOD2 IBD9
4 inflammatory bowel disease 2 35.3 NOD2 IBD2
5 inflammatory bowel disease 6 35.2 NOD2 IBD6
6 inflammatory bowel disease 3 35.1 NOD2 IBD3
7 inflammatory bowel disease 18 35.0 NOD2 IBD18
8 inflammatory bowel disease 5 34.8 NOD2 IBD5
9 inflammatory bowel disease 25, autosomal recessive 12.9
10 inflammatory bowel disease 1 12.9
11 inflammatory bowel disease 10 12.9
12 inflammatory bowel disease 17 12.9
13 inflammatory bowel disease 19 12.9
14 inflammatory bowel disease 28, autosomal recessive 12.9
15 inflammatory bowel disease 14 12.8
16 inflammatory bowel disease 13 12.8
17 inflammatory bowel disease 29 12.8
18 inflammatory bowel disease 4 12.8
19 inflammatory bowel disease 15 12.8
20 inflammatory bowel disease 20 12.8
21 inflammatory bowel disease 24 12.8
22 inflammatory bowel disease 28 12.8
23 inflammatory bowel disease, immunodeficiency, and encephalopathy 12.8
24 inflammatory bowel disease 12 12.8
25 inflammatory bowel disease 16 12.8
26 inflammatory bowel disease 21 12.8
27 inflammatory bowel disease 26 12.8
28 inflammatory bowel disease 22 12.8
29 inflammatory bowel disease 23 12.8
30 inflammatory bowel disease 27 12.8
31 inflammatory bowel disease 11 12.8
32 inflammatory bowel disease 25 12.7
33 ulcerative colitis 12.4
34 infantile inflammatory bowel disease with neurological involvement 12.3
35 inflammatory bowel disease-recurrent sinopulmonary infections syndrome 12.3
36 immune dysregulation with inflammatory bowel disease 12.3
37 immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome 12.3
38 rare inflammatory bowel disease 12.3
39 gastrointestinal defects and immunodeficiency syndrome 12.2
40 crohn's disease 12.1
41 cholangitis, primary sclerosing 11.9
42 crohn's colitis 11.8
43 irritable bowel syndrome 11.8
44 spondyloarthropathy 1 11.7
45 ileitis 11.7
46 immunodeficiency, common variable, 8, with autoimmunity 11.7
47 colitis 11.7
48 ileocolitis 11.7
49 immunodeficiency, common variable, 11 11.7
50 collagenous colitis 11.7

Graphical network of the top 20 diseases related to Inflammatory Bowel Disease:



Diseases related to Inflammatory Bowel Disease
Sources

Symptoms & Phenotypes for Inflammatory Bowel Disease

About this section
Sources

Drugs & Therapeutics for Inflammatory Bowel Disease

About this section

Drugs for Inflammatory Bowel Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 508)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Copper Approved, Investigational Phase 4 7440-50-8 27099
2
Clofazimine Approved, Investigational Phase 4 2030-63-9 2794
3
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
4
Prucalopride Approved Phase 4 179474-81-8
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
7
Fidaxomicin Approved Phase 4 873857-62-6
8
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
9
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
10
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
11
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
12
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
13
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
14
Ibuprofen Approved Phase 4 15687-27-1 3672
15
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
16
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
17
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
18
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
19
Acetaminophen Approved Phase 4 103-90-2 1983
20 Orange Approved Phase 4
21
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
22 Artichoke Approved Phase 4
23 Strawberry Approved Phase 4
24
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
25
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
26
leucovorin Approved Phase 4 58-05-9 6006 143
27
carbamide peroxide Approved Phase 4 124-43-6
28
Clarithromycin Approved Phase 4 81103-11-9 84029
29
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
30
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
31
Ondansetron Approved Phase 4 99614-02-5 4595
32
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
33
Vancomycin Approved Phase 4 1404-90-6 441141 14969
34
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
35
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
36
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
37
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
38
Racepinephrine Approved Phase 4 329-65-7 838
39
Ustekinumab Approved, Investigational Phase 4 815610-63-0
40
Zinc oxide Approved Phase 4 1314-13-2
41
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
42
Dalteparin Approved Phase 4 9005-49-6
43
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
44
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
45
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6, 59-43-8 1130
46 Rebamipide Investigational Phase 4 90098-04-7
47
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
48 retinol Phase 4
49 Retinol palmitate Phase 4
50 Serotonin Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1431)
# Name Status NCT ID Phase Drugs
1 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
2 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
3 Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass Unknown status NCT02086968 Phase 4 Injectafer;Ferrous Sulfate tablets
4 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
5 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
6 Optimal Substitution Dose of the Vitamin D During Winter Time in Patient With Inflammatory Bowel Diseases (IBD) Unknown status NCT02958501 Phase 4 Colecalciferol
7 Does Clinical Response Correlate With Serum Certolizumab Levels? A Prospective Open Label Trial of Adult Patients With Active Crohn's Disease (APOLLO) Unknown status NCT02597829 Phase 4 Certolizumab Pegol
8 Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial Unknown status NCT01479660 Phase 4 Probiotic
9 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
10 Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD Unknown status NCT03059849 Phase 4 Adalimumab
11 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4 Rifabutin, Clarithromycin, and Clofazimine
12 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
13 EFFICACY, TOLERABILITY, AND SAFETY OF DIFFERENT BOWEL PREPARATIONS FOR COLONOSCOPY IN CHILDREN Unknown status NCT01711437 Phase 4
14 Spectrum of Gastrointestinal Microbiota in Patients With IBS-D Before and After Treatment With VSL#3. Unknown status NCT01638208 Phase 4 VSL#3
15 Assessment of the Participation Rate and the Diagnostic Accuracy of a Colorectal Cancer Screening Program: CT Colonography Versus Flexible Sigmoidoscopy. Evaluation of a New Model Based on Telediagnosis Unknown status NCT01739608 Phase 4
16 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
17 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
18 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
19 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
20 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
21 Nurse Administered Propofol Sedation vs. Standard Therapy for Colonoscopy in Patients With IBD. A Randomised Controlled Study on Satisfaction and Adherence to Treatment Program. Completed NCT01934088 Phase 4 Propofol;Midazolam;Fentanyl
22 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
23 Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
24 Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4 fidaxomicin
25 Gene Regulation by Thiazolidinediones Completed NCT00567593 Phase 4 Rosiglitazone
26 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
27 Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients Completed NCT02461758 Phase 4
28 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
29 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease: A Novel Adjunctive Therapy for Chronic Inflammatory Illness Completed NCT02162862 Phase 4 bupropion-SR
30 Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
31 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
32 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
33 Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy Completed NCT00746395 Phase 4 Lubiprostone;Placebo
34 Precision Dosing Versus Conventional Dosing of Infliximab Maintenance Therapy: a Randomized Controlled Multicenter Study in Patients With IBD in Clinical Remission Completed NCT02453776 Phase 4 PRECISION dosing Infliximab
35 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial Completed NCT02010762 Phase 4 Vitamin D;Placebo
36 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
37 Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue Completed NCT01991314 Phase 4 Ferrous sulphate
38 A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
39 Double-Blind, Placebo-Controlled, Randomized Two-Week Study, Comparing Small Bowel Lesions Associated With Celecoxib (200 mg BID) vs. Ibuprofen (800 mg TID) Plus Omeprazole (20 mg QD) Completed NCT00640809 Phase 4 Celecoxib;Ibuprofen plus Omeprazole
40 Compression Anastomosis: Initial Clinical Experience With the ColonRingTM Completed NCT01056913 Phase 4
41 A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
42 Serological Response to Pneumococcal Vaccination in Crohn's Disease: A Prospective Multicenter Study Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
43 Prospective Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients Undergoing CT and MR Enterography Completed NCT02946203 Phase 4
44 Lactobacillus Reuteri Reduces Pulmonary Exacerbations and Upper Respiratory Tract Infections in CF Patients With Mild-to-moderate Lung Disease. LR Administration Might Have a Beneficial Effect on the Disease Course of Cystic Fibrosis. Completed NCT01737983 Phase 4
45 A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients Completed NCT01215890 Phase 4 risedronate;placebo
46 Pneumococcal Vaccination of Crohn Patients - A Randomized, Non-blinded Phase 4 Clinical Trial With the Purpose of Investigating the Immune Response Against Two Different Pneumococcal Vaccines in Patients With Crohn's Disease Completed NCT01947010 Phase 4
47 A Prospective Audit of Tolerability, Mucosal Cleansing Efficacy and Mucosal Abnormalities Associated With Standard Orally Administered Colon Cleansing Preparations for Colonoscopy Completed NCT00750763 Phase 4 Colonlytely;Picolax/Picoprep;Fleet
48 2L Oral Bi-PegLyte Versus 2L Oral MoviPrep Regimen for Outpatient Colonic Preparation: A Randomized, Non-Inferiority Open Trial Completed NCT01865916 Phase 4 Polyethylene Glycol (PEG) and 15 mg Bisacodyl;Polyethylene Glycol (PEG) + ascorbic acid
49 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
50 Mesalamine to Reduce T Cell Activation in HIV Infection Completed NCT01090102 Phase 4 Mesalamine (5-aminosalicylic acid, Apriso);Placebo

Search NIH Clinical Center for Inflammatory Bowel Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


clidinium
Clidinium bromide
Cromolyn
Cromolyn Sodium

Cochrane evidence based reviews: inflammatory bowel diseases

Sources

Genetic Tests for Inflammatory Bowel Disease

About this section

Genetic tests related to Inflammatory Bowel Disease:

# Genetic test Affiliating Genes
1 Inflammatory Bowel Disease 29
Sources

Anatomical Context for Inflammatory Bowel Disease

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Inflammatory Bowel Disease:

19
All Parts Of Digestive Tract

MalaCards organs/tissues related to Inflammatory Bowel Disease:

40
Colon, T Cells, Bone, Liver, Testes, Neutrophil, Skin
Sources

Publications for Inflammatory Bowel Disease

About this section

Articles related to Inflammatory Bowel Disease:

(show top 50) (show all 36314)
# Title Authors PMID Year
1
Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo. 54 61
20361960 2010
2
Association analysis of myosin IXB and type 1 diabetes. 54 61
20303373 2010
3
Anti-TNF therapy in inflammatory bowel diseases: a huge review. 54 61
20485259 2010
4
IL-6 may modulate the skeletal response to glucocorticoids during exacerbations of inflammatory bowel disease. 54 61
20229252 2010
5
Replication and meta-analysis of 13,000 cases defines the risk for interleukin-23 receptor and autophagy-related 16-like 1 variants in Crohn's disease. 54 61
20485703 2010
6
Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. 54 61
20493732 2010
7
Cell-specific inhibition of p38alpha as a therapeutic strategy for inflammatory bowel disease. 54 61
20184972 2010
8
The use of GLP-2 and related growth factors in intestinal diseases. 54 61
20336592 2010
9
Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis. 54 61
19710105 2010
10
Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. 54 61
20454450 2010
11
Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis. 54 61
20228197 2010
12
Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. 54 61
20138213 2010
13
Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. 54 61
19878610 2010
14
GanedenBC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. 54 61
20331905 2010
15
Neutrophil gelatinase-associated lipocalin levels in patients with crohn disease undergoing treatment with infliximab. 54 61
20061984 2010
16
Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease. 54 61
19714744 2010
17
Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients. 54 61
20175817 2010
18
Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia. 54 61
20446955 2010
19
[Anti-inflammatory effect of PPARgamma agonists: basics and clinical applications]. 54 61
20158097 2010
20
[Use of TNFalpha antibodies in treatment of inflammatory bowel disease]. 54 61
20160771 2010
21
Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. 54 61
20210765 2010
22
Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs. 54 61
19960028 2010
23
Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-gamma signaling in a murine model of inflammatory bowel disease. 54 61
19698701 2010
24
Lymphoid tyrosine phosphatase R620W variant and inflammatory bowel disease in Tunisia. 54 61
20101775 2010
25
Interaction of the major inflammatory bowel disease susceptibility alleles in Crohn's disease patients. 54 61
20066736 2010
26
Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions. 54 61
19808045 2010
27
Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. 54 61
19740775 2009
28
Dislocation of Rab13 and vasodilator-stimulated phosphoprotein in inactive colon epithelium in patients with Crohn's disease. 54 61
19885626 2009
29
Actobiotics as a novel method for cytokine delivery. 54 61
20074282 2009
30
Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. 54 61
19363798 2009
31
Role of ATG16L1 Thr300Ala polymorphism in inflammatory bowel disease: a Study in the Spanish population and a meta-analysis. 54 61
19575361 2009
32
Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. 54 61
19639558 2009
33
Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. 54 61
19839006 2009
34
Interleukin-10 in inflammatory bowel disease. 54 61
19890110 2009
35
The role of resistin as a regulator of inflammation: Implications for various human pathologies. 54 61
19740705 2009
36
Sulphasalazine accelerates apoptosis in neutrophils exposed to immune complex: Role of caspase pathway. 54 61
19473188 2009
37
Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. 54 61
19874614 2009
38
Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. 54 61
19817673 2009
39
PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease. 54 61
19462432 2009
40
Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? 54 61
19711064 2009
41
[TNF-alpha blocking therapy in chronic inflammatory bowel disease]. 54 61
19740722 2009
42
A component of polysaccharide peptidoglycan complex on Lactobacillus induced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer. 54 61
19740306 2009
43
STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. 54 61
19648026 2009
44
Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. 54 61
19322899 2009
45
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. 54 61
19291780 2009
46
pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling. 54 61
19570976 2009
47
[The cytokines in inflammatory bowel disease]. 54 61
19724079 2009
48
Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. 54 61
19682195 2009
49
Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs. 54 61
19604082 2009
50
Nuclear pregnane X receptor single nucleotide polymorphism (-25385C/T) is not associated with inflammatory bowel disease in pediatric patients. 54 61
19516190 2009
Sources

Variations for Inflammatory Bowel Disease

About this section

ClinVar genetic disease variations for Inflammatory Bowel Disease:

6 (show top 50) (show all 84) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IL10RA NM_001558.3(IL10RA):c.781C>T (p.Arg261Trp)SNV Conflicting interpretations of pathogenicity 252589 rs201396764 11:117866396-117866396 11:117995681-117995681
2 IL10RA NM_001558.3(IL10RA):c.931T>C (p.Leu311=)SNV Conflicting interpretations of pathogenicity 286333 rs148808529 11:117869550-117869550 11:117998835-117998835
3 IL10RA NM_001558.3(IL10RA):c.144C>T (p.Ile48=)SNV Conflicting interpretations of pathogenicity 302537 rs140466541 11:117859173-117859173 11:117988458-117988458
4 IL10RA NM_001558.3(IL10RA):c.96G>A (p.Val32=)SNV Conflicting interpretations of pathogenicity 302536 rs377525753 11:117859125-117859125 11:117988410-117988410
5 IL10RA NM_001558.3(IL10RA):c.337G>A (p.Val113Ile)SNV Conflicting interpretations of pathogenicity 302544 rs4252303 11:117860305-117860305 11:117989590-117989590
6 IL10RA NM_001558.3(IL10RA):c.810+10G>ASNV Conflicting interpretations of pathogenicity 302552 rs12290349 11:117866435-117866435 11:117995720-117995720
7 IL10RA NM_001558.3(IL10RA):c.72A>C (p.Thr24=)SNV Conflicting interpretations of pathogenicity 302534 rs560128585 11:117859101-117859101 11:117988386-117988386
8 IL10RA NM_001558.3(IL10RA):c.696C>T (p.Thr232=)SNV Conflicting interpretations of pathogenicity 302549 rs4252311 11:117866311-117866311 11:117995596-117995596
9 IL10RA NM_001558.3(IL10RA):c.1188G>A (p.Arg396=)SNV Conflicting interpretations of pathogenicity 302555 rs35465632 11:117869807-117869807 11:117999092-117999092
10 IL10RB NM_000628.5(IL10RB):c.73G>A (p.Glu25Lys)SNV Conflicting interpretations of pathogenicity 339691 rs80027572 21:34640722-34640722 21:33268417-33268417
11 IL10RB NM_000628.5(IL10RB):c.484G>A (p.Gly162Ser)SNV Uncertain significance 339694 rs770980693 21:34652209-34652209 21:33279904-33279904
12 IL10RB NM_000628.5(IL10RB):c.*546G>ASNV Uncertain significance 339704 rs886057006 21:34669208-34669208 21:33296903-33296903
13 IL10RB NM_000628.5(IL10RB):c.*816T>CSNV Uncertain significance 339712 rs118117891 21:34669478-34669478 21:33297173-33297173
14 IL10RB NM_000628.5(IL10RB):c.-94C>ASNV Uncertain significance 339688 rs556338583 21:34638677-34638677 21:33266372-33266372
15 IL10RB NM_000628.5(IL10RB):c.131C>T (p.Ala44Val)SNV Uncertain significance 339692 rs182073431 21:34640780-34640780 21:33268475-33268475
16 IL10RB NM_000628.5(IL10RB):c.*17A>GSNV Uncertain significance 339696 rs886057003 21:34668679-34668679 21:33296374-33296374
17 IL10RB NM_000628.5(IL10RB):c.*20C>TSNV Uncertain significance 339697 rs886057004 21:34668682-34668682 21:33296377-33296377
18 IL10RB NM_000628.5(IL10RB):c.*365C>TSNV Uncertain significance 339702 rs886057005 21:34669027-34669027 21:33296722-33296722
19 IL10RA NM_001558.3(IL10RA):c.188+3G>ASNV Uncertain significance 302540 rs780334422 11:117859220-117859220 11:117988505-117988505
20 IL10RA NM_001558.3(IL10RA):c.336C>T (p.Thr112=)SNV Uncertain significance 302543 rs192749274 11:117860304-117860304 11:117989589-117989589
21 IL10RB NM_000628.5(IL10RB):c.174-14T>GSNV Uncertain significance 339693 rs200472684 21:34648887-34648887 21:33276582-33276582
22 IL10RA NM_001558.3(IL10RA):c.*756T>CSNV Uncertain significance 302566 rs188436763 11:117871112-117871112 11:118000397-118000397
23 IL10RA NM_001558.3(IL10RA):c.*968G>ASNV Uncertain significance 302570 rs562515149 11:117871324-117871324 11:118000609-118000609
24 IL10RA NM_001558.3(IL10RA):c.*1684G>ASNV Uncertain significance 302578 rs143719655 11:117872040-117872040 11:118001325-118001325
25 IL10RB NM_000628.5(IL10RB):c.-72C>ASNV Uncertain significance 339690 rs45607743 21:34638699-34638699 21:33266394-33266394
26 IL10RB NM_000628.5(IL10RB):c.727G>A (p.Ala243Thr)SNV Uncertain significance 339695 rs1058861 21:34660489-34660489 21:33288184-33288184
27 IL10RB NM_000628.5(IL10RB):c.*515C>TSNV Uncertain significance 339703 rs767017864 21:34669177-34669177 21:33296872-33296872
28 IL10RB NM_000628.5(IL10RB):c.*616A>GSNV Uncertain significance 339708 rs886057009 21:34669278-34669278 21:33296973-33296973
29 IL10RB NM_000628.5(IL10RB):c.*796T>CSNV Uncertain significance 339711 rs886057010 21:34669458-34669458 21:33297153-33297153
30 IL10RB NM_000628.5(IL10RB):c.-74C>ASNV Uncertain significance 339689 rs56368587 21:34638697-34638697 21:33266392-33266392
31 IL10RA NM_001558.3(IL10RA):c.*104C>GSNV Uncertain significance 302560 rs886047710 11:117870460-117870460 11:117999745-117999745
32 IL10RA NM_001558.3(IL10RA):c.*133C>TSNV Uncertain significance 302561 rs752174 11:117870489-117870489 11:117999774-117999774
33 IL10RA NM_001558.3(IL10RA):c.*676C>TSNV Uncertain significance 302565 rs756303257 11:117871032-117871032 11:118000317-118000317
34 IL10RA NM_001558.3(IL10RA):c.*854C>GSNV Uncertain significance 302567 rs535662153 11:117871210-117871210 11:118000495-118000495
35 IL10RA NM_001558.3(IL10RA):c.*1555C>TSNV Uncertain significance 302576 rs182393130 11:117871911-117871911 11:118001196-118001196
36 IL10RA NM_001558.3(IL10RA):c.*1664A>GSNV Uncertain significance 302577 rs886047713 11:117872020-117872020 11:118001305-118001305
37 IL10RA NM_001558.3(IL10RA):c.*1722T>CSNV Uncertain significance 302579 rs886047714 11:117872078-117872078 11:118001363-118001363
38 IL10RA NM_001558.3(IL10RA):c.25C>T (p.Leu9=)SNV Uncertain significance 302530 rs886047706 11:117857207-117857207 11:117986492-117986492
39 IL10RA NM_001558.3(IL10RA):c.80C>T (p.Pro27Leu)SNV Uncertain significance 302535 rs755758777 11:117859109-117859109 11:117988394-117988394
40 IL10RA NM_001558.3(IL10RA):c.706G>A (p.Val236Ile)SNV Uncertain significance 302550 rs35473928 11:117866321-117866321 11:117995606-117995606
41 IL10RA NM_001558.3(IL10RA):c.1323G>A (p.Val441=)SNV Uncertain significance 302558 rs746663189 11:117869942-117869942 11:117999227-117999227
42 IL10RA NM_001558.3(IL10RA):c.*1352G>ASNV Uncertain significance 302573 rs570165681 11:117871708-117871708 11:118000993-118000993
43 IL10RA NM_001558.3(IL10RA):c.320G>A (p.Arg107Gln)SNV Uncertain significance 302542 rs145949718 11:117860288-117860288 11:117989573-117989573
44 IL10RA NM_001558.3(IL10RA):c.447G>A (p.Lys149=)SNV Uncertain significance 302545 rs750580462 11:117864035-117864035 11:117993320-117993320
45 IL10RA NM_001558.3(IL10RA):c.*1375C>ASNV Uncertain significance 302574 rs141609122 11:117871731-117871731 11:118001016-118001016
46 IL10RA NM_001558.3(IL10RA):c.785G>A (p.Arg262His)SNV Uncertain significance 302551 rs202121581 11:117866400-117866400 11:117995685-117995685
47 IL10RA NM_001558.3(IL10RA):c.-70C>TSNV Uncertain significance 302528 rs185159635 11:117857113-117857113 11:117986398-117986398
48 IL10RA NM_001558.3(IL10RA):c.-54T>CSNV Uncertain significance 302529 rs886047705 11:117857129-117857129 11:117986414-117986414
49 IL10RA NM_001558.3(IL10RA):c.67+11G>ASNV Uncertain significance 302531 rs376956484 11:117857260-117857260 11:117986545-117986545
50 IL10RA NM_001558.3(IL10RA):c.67+13G>ASNV Uncertain significance 302532 rs886047707 11:117857262-117857262 11:117986547-117986547
Sources

Expression for Inflammatory Bowel Disease

About this section
Search GEO for disease gene expression data for Inflammatory Bowel Disease.
Sources

Pathways for Inflammatory Bowel Disease

About this section

Pathways related to Inflammatory Bowel Disease according to KEGG:

36
# Name Kegg Source Accession
1 Inflammatory bowel disease (IBD) hsa05321
2 Antigen processing and presentation hsa04612
3 Cytokine-cytokine receptor interaction hsa04060
4 JAK-STAT signaling pathway hsa04630
5 Autophagy - animal hsa04140
Sources

GO Terms for Inflammatory Bowel Disease

About this section
Sources

Sources for Inflammatory Bowel Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....